Tower Research Capital LLC (Trc) Madrigal Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 340 shares of MDGL stock, worth $115,018. This represents 0.0% of its overall portfolio holdings.

Number of Shares

340

Previous 2,655 87.19%

Holding current value

$115,018

Previous $743,000 90.31%

% of portfolio

0.0%

Previous 0.01%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$212.22 - $292.96 $491,289 - $678,202	-2,315 Reduced 87.19%	340 $72,000
Q2 2024 Aug 13, 2024	BUY	$193.33 - $291.99 $336,394 - $508,062	1,740 Added 190.16%	2,655 $743,000
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $239,403 - $395,672	-1,397 Reduced 60.42%	915 $244,000
Q4 2023 Feb 13, 2024	BUY	$120.4 - $237.13 $30,340 - $59,756	252 Added 12.23%	2,312 $534,000
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $53,596 - $82,861	367 Added 21.68%	2,060 $300,000
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $256,888 - $393,120	1,260 Added 290.99%	1,693 $391,000
Q1 2023 May 09, 2023	SELL	$231.06 - $307.08 $649,047 - $862,587	-2,809 Reduced 86.64%	433 $105,000
Q4 2022 Feb 10, 2023	SELL	$58.39 - $296.54 $149,069 - $757,066	-2,553 Reduced 44.06%	3,242 $941,000
Q3 2022 Nov 10, 2022	BUY	$60.57 - $79.51 $200,607 - $263,337	3,312 Added 133.39%	5,795 $377,000
Q2 2022 Aug 15, 2022	BUY	$58.04 - $100.2 $83,693 - $144,488	1,442 Added 138.52%	2,483 $177,000
Q1 2022 May 12, 2022	SELL	$55.89 - $101.89 $56,001 - $102,093	-1,002 Reduced 49.05%	1,041 $102,000
Q4 2021 Feb 14, 2022	BUY	$72.34 - $95.09 $56,352 - $74,075	779 Added 61.63%	2,043 $173,000
Q3 2021 Nov 15, 2021	SELL	$78.35 - $105.02 $81,405 - $109,115	-1,039 Reduced 45.12%	1,264 $101,000
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $181,278 - $256,605	1,865 Added 425.8%	2,303 $224,000
Q1 2021 May 17, 2021	BUY	$108.54 - $125.2 $43,307 - $49,954	399 Added 1023.08%	438 $51,000
Q4 2020 Feb 16, 2021	SELL	$110.06 - $133.7 $43,473 - $52,811	-395 Reduced 91.01%	39 $4,000
Q3 2020 Nov 16, 2020	SELL	$99.78 - $124.21 $141,088 - $175,632	-1,414 Reduced 76.52%	434 $51,000
Q2 2020 Aug 13, 2020	BUY	$60.13 - $125.71 $53,515 - $111,881	890 Added 92.9%	1,848 $209,000
Q1 2020 May 15, 2020	BUY	$66.76 - $93.49 $52,873 - $74,044	792 Added 477.11%	958 $64,000
Q4 2019 Feb 07, 2020	SELL	$84.28 - $118.5 $26,463 - $37,209	-314 Reduced 65.42%	166 $15,000
Q3 2019 Nov 05, 2019	BUY	$84.4 - $106.53 $40,512 - $51,134	480 New	480 $41,000
Q3 2018 Nov 13, 2018	SELL	$207.3 - $300.31 $32,960 - $47,749	-159 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$101.55 - $313.9 $14,318 - $44,259	141 Added 783.33%	159 $44,000
Q1 2018 May 15, 2018	BUY	$93.35 - $149.04 $1,680 - $2,682	18 New	18 $2,000
Q4 2017 Feb 09, 2018	SELL	$39.35 - $97.37 $8,853 - $21,908	-225 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$15.48 - $46.19 $3,483 - $10,392	225	225 $10,000

Others Institutions Holding MDGL

# of Institutions

294

Shares Held

21.9M

Call Options Held

819K

Put Options Held

644K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.79B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Madrigal Pharmaceuticals, Inc. Transaction History